Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Open access
Ott, Brian R., Daiello, Lori A., Dahabreh, Issa J., Springate, Beth A., Bixby, Kimberly, Murali, Manjari, Trikalinos, Thomas A.·2015·Journal of General Internal Medicine

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11606-014-3115-3

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 59

  1. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21(1):95–102. · DOI
  2. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis. 2012;21(6):436–44. · DOI
  3. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al. Statins and serum cholesterol’s associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health. 2011;65(11):949–57. · DOI
  4. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29(7):800–11. · DOI · Paper page
  5. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy. 2001;21(6):767–9. · DOI
  6. Parker BA, Polk DM, Rabdya V, et al. Changes in memory function and neuronal activation associated with atorvastatin therapy. Pharmacotherapy. 2010;30(6):236e–40e. · DOI
  7. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871–80. · DOI · Paper page
  8. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer’s disease. Neuroepidemiology. 2004;23(1–2):94–8. · DOI · Paper page
  9. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 2005;62(2):217–24. · DOI · Paper page
  10. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer’s disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23(3):194–201. · DOI
  11. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108(7):538–46. · DOI · Paper page
  12. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117(11):823–9. · DOI · Paper page
  13. Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother. 2012;10(5):296–302. · DOI
  14. Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549–57. · DOI
  15. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875–81. · DOI
  16. Macedo AF, Taylor FC, Casas JP, Adler A, Prieto-Merino D, Ebrahim S. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014;12:51. · DOI · Paper page
  17. Swiger KJ, Manalac RJ, Blumenthal RS, Blaha MJ, Martin SS. Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc. 2013;88(11):1213–21. · DOI · Paper page
  18. McGuinness B, O’Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010;8:CD007514.
  19. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
  20. Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr. 2012; p. 819–24. · DOI · Paper page
  21. Mohs RC. The Alzheimer’s Disease Assessment Scale. Int Psychogeriatr. 1996;8(2):195–203. · DOI
  22. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98. · DOI · Paper page
  23. Van Den Noortgate W, Onghena P. Estimating the mean effect size in meta-analysis: bias, precision, and mean squared error of different weighting methods. Behav Res Methods Instrum Comput. 2003;35(4):504–11. · DOI
  24. Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. Res Synth Meth. 2010;1(1):39–65. · DOI · Paper page
  25. Sierra S, Ramos MC, Molina P, Esteo C, Vazquez JA, Burgos JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis. 2011;23(2):307–18. · DOI · Paper page
  26. Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoogerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25(7):1250–1. · DOI
  27. Carlsson CM, Papcke-Benson K, Carnes M, McBride PE, Stein JH. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs Aging. 2002;19(10):793–805. · DOI
  28. Carlsson CM, Gleason CE, Hess TM, et al. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J Alzheimers Dis. 2008;13(2):187–97. · DOI
  29. Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757–67. · DOI · Paper page
  30. Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol. 1995;39(3):333–6. · DOI
  31. Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol. 1995;18(4):209–14. · DOI
  32. Gibellato MG, Moore JL, Selby K, Bower EA. Effects of lovastatin and pravastatin on cognitive function in military aircrew. Aviat Space Environ Med. 2001;72(9):805–12.
  33. Harrison RW, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol. 1994;37(3):231–6. · DOI
  34. Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol. 1994;34(10):989–96. · DOI
  35. Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA. 2008;300(3):287–94. · DOI · Paper page
  36. Posvar EL, Radulovic LL, Cilla DD Jr, Whitfield LR, Sedman AJ. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 1996;36(8):728–31. · DOI
  37. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Roehrs T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol. 1992;15(6):426–32. · DOI
  38. Sanchez-Aguilar M, Tapia-Perez JH, Sanchez-Rodriguez JJ, et al. Effect of rosuvastatin on cytokines after traumatic head injury. J Neurosurg. 2013;118(3):669–75. · DOI
  39. Sano M, Bell KL, Galasko D, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77(6):556–63. · DOI · Paper page
  40. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the cholesterol reduction in seniors program (CRISP) pilot study. J Am Geriatr Soc. 1997;45(1):8–14. · DOI
  41. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52(3):346–50. · DOI · Paper page
  42. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol. 2005;62(5):753–7. · DOI · Paper page
  43. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3–7. · DOI
  44. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer’s disease. Acta Neurol Scand Suppl. 2006;185:78–86. · DOI
  45. Sparks DL, Lemieux SK, Haut MW, et al. Hippocampal volume change in the Alzheimer disease cholesterol-lowering treatment trial. Cleve Clin J Med. 2008;75(Suppl 2):S87–S93. · DOI
  46. Summers MJ, Oliver KR, Coombes JS, Fassett RG. Effect of atorvastatin on cognitive function in patients from the lipid lowering and onset of renal disease (LORD) trial. Pharmacotherapy. 2007;27(2):183–90. · DOI
  47. Tapia-Perez J, Sanchez-Aguilar M, Torres-Corzo JG, et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma. 2008;25(8):1011–7. · DOI
  48. Tendolkar I, Enajat M, Zwiers MP, et al. One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial. Int J Geriatr Psychiatry. 2012;27(1):49–58. · DOI
  49. Schrag A, Schott JM. What is the clinically relevant change on the ADAS-Cog? J Neurol Neurosurg Psychiatry. 2012;83(2):171–3. · DOI
  50. Simpson RJ Jr, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462–71. · DOI
  51. Vural K, Tuglu MI. Neurotoxic effect of statins on mouse neuroblastoma NB2a cell line. Eur Rev Med Pharmacol Sci. 2011;15(9):985–91.
  52. MacDonald JS, Gerson RJ, Kornbrust DJ, et al. Preclinical evaluation of lovastatin. Am J Cardiol. 1988;62(15):16J–27J. · DOI · Paper page
  53. Stuart SA, Robertson JD, Marrion NV, Robinson ES. Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PLoS One. 2013;8(9):e75467. · DOI
  54. Elkind MS, Sacco RL, Macarthur RB, et al. High-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis. 2009;28(3):266–75. · DOI
  55. Cuciureanu M, Vlase L, Muntean D, Varlan I, Cuciureanu R. Grapefruit juice–drug interactions: importance for pharmacotherapy. Rev Med Chir Soc Med Nat Iasi. 2010;114(3):885–91.
  56. Hare JT, Elliott DP. Grapefruit juice and potential drug interactions. Consult Pharm. 2003;18(5):466–72.
  57. Goh IX, How CH, Tavintharan S. Cytochrome P450 drug interactions with statin therapy. Singap Med J. 2013;54(3):131–5. · DOI
  58. Leung A, Schaefer EW, Tempelhof MW, Stone NJ. Emphasizing statin safety in the hospitalized patient: a review. Am J Med. 2012;125(9):845–53. · DOI
  59. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285(4):437–43. · DOI · Paper page

Cited by

See all 239

Metadata

Authors
Ott, B. R., Daiello, L. A., Dahabreh, I. J., Springate, B. A., Bixby, K., Murali, M., & Trikalinos, T. A.
Venue
Journal of General Internal Medicine
Published
2015-01-10
Volume
30
Issue
3
Pages
348-358
ISSN
  • 0884-8734 (ISSN-L)
  • 1525-1497
OpenAlex
W2021222203
Cited by
239
References
14
FWCI
5.88
Type
journal article
Language
en
Open access
bronze
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1007/s11606-014-3115-3
The paper
Ott, B. R., Daiello, L. A., Dahabreh, I. J., Springate, B. A., Bixby, K., Murali, M., & Trikalinos, T. A. (2015). Do Statins Impair Cognition? A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-014-3115-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.